FY2025 EPS Estimates for Opthea Raised by Leerink Partnrs

Opthea Limited (NASDAQ:OPT) – Research analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for Opthea in a report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($1.15) per share for the year, up from their prior forecast of ($1.20). The consensus estimate for Opthea’s current full-year earnings is ($1.40) per share. Leerink Partnrs also issued estimates for Opthea’s FY2026 earnings at ($1.05) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $1.60 EPS.

Separately, HC Wainwright dropped their target price on Opthea from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.

Opthea Trading Down 1.0 %

Shares of Opthea stock opened at $5.03 on Friday. Opthea has a twelve month low of $1.60 and a twelve month high of $5.45. The business’s 50 day simple moving average is $3.55 and its 200-day simple moving average is $3.06.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.